Scarica l'app Stockscreener
2.13
1.39%
-0.03
Dopo l'orario di chiusura:
2.17
0.04
+1.88%
Precedente Chiudi:
$2.16
Aprire:
$2.14
Volume 24 ore:
27,968
Relative Volume:
0.35
Capitalizzazione di mercato:
$9.67M
Reddito:
-
Utile/perdita netta:
$-31.88M
Rapporto P/E:
-2.84
EPS:
-0.75
Flusso di cassa netto:
$-25.20M
1 W Prestazione:
-11.62%
1M Prestazione:
+6.50%
6M Prestazione:
-56.50%
1 anno Prestazione:
-69.66%
Intervallo 1D:
$2.09
$2.2847
Intervallo di 1 settimana:
$2.08
$2.5107
Portata 52W:
$1.91
$16.70
In 8 Bio Inc Stock (INAB) Company Profile
Nome
In 8 Bio Inc
Settore
Industria
Telefono
(646) 600-6438
Indirizzo
EMPIRE STATE BUILDING, NEW YORK
Confronta INAB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
2.13 | 9.81M | 0 | -31.88M | -25.20M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.90 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
470.27 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.42 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
815.61 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
316.15 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-03-18 | Iniziato | Laidlaw | Buy |
| 2022-08-30 | Iniziato | H.C. Wainwright | Buy |
In 8 Bio Inc Borsa (INAB) Ultime notizie
Inmune Bio Inc Announces Participation in Dermatologic Panel - TradingView
Oct 22 CEO Panel: INmune Bio's CORDStrom for RDEB — David Moss at Maxim Growth Summit in NYC - Stock Titan
Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108 - GlobeNewswire
Is Mustang Bio Inc. stock ready for a breakoutJuly 2025 Closing Moves & Free Low Drawdown Momentum Trade Ideas - newser.com
Layoff Tracker: Ferring To Cut 500 Employees as Part of Business Model Shift - BioSpace
Palisade Bio, Inc. Cancels Special Meeting of Stockholders - TradingView
Bio, semiconductor, content firms to reboot Korea’s IPO market - The Korea Economic Daily Global Edition
Nuvation Bio Inc. (NUVB): A Bull Case Theory - Insider Monkey
PlayStation sale round-up for North America October 8, 2025 - TrueTrophies
Brokerages Set Gossamer Bio, Inc. (NASDAQ:GOSS) Price Target at $8.50 - Defense World
Morning Market Movers: SPRB, LXEO, BMEA, Seeing Big Swings - RTTNews
70.0M shares: Adicet Bio Prices $80M Registered Direct Offering - Stock Titan
Morning Market Movers: DBVT, CLPT, DWTX, Seeing Big Swings - RTTNews
$138M Raised: Palisade Bio Closes Upsized Offering to Fund Phase 2 PALI-2108 - Stock Titan
Biopsy Devices Market Poised for Steady Growth by 2032, Fueled by Innovation and Increasing Surgical Procedures | DelveInsight - The Globe and Mail
Palisade Bio Inc. (PALI) Stock Price | Live Quotes & Charts | NSC - StocksToTrade
Mucopolysaccharidosis III Pipeline 2025: Pioneering Clinical - openPR.com
Wheeler Bio Appoints Jay Benson as Chief Operating Officer - PR Newswire
Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock - Yahoo Finance
Biotech Adicet Bio Issues New Employee Stock Options at $0.81 Under Special Inducement Plan - Stock Titan
Cancer Detection Biotech bioAffinity Technologies Raises $4.8M Through Public Stock Offering at $2.50 - Stock Titan
United Natural Foods Posts Upbeat Results, Joins AnaptysBio, Semtech, UiPath And Other Big Stocks Moving Higher On Tuesday - Benzinga
180-Patient Phase 3 Trial: Nuvation Bio Tests IBTROZI for Early-Stage Lung Cancer Prevention - Stock Titan
Climb Bio stock price target raised to $8 from $7 at BTIG on CLYM116 potential - Investing.com India
24-Week TSLP Inhibition: Upstream Bio's Verekitug Shows Breakthrough Respiratory Disease Treatment Data - Stock Titan
KALA BIO Announces Topline Results from CHASE Phase 2b - GlobeNewswire
KALA BIO Announces Topline Results from CHASE Phase 2b Clinical Trial Evaluating KPI-012 for the Treatment of Persistent Corneal Epithelial Defect (PCED) Did Not Meet Primary Endpoint - Yahoo Finance
Climb Bio Announces CLYM116 Preclinical Data Highlighting Potential for Best-In-Class Therapeutic for IgAN - GlobeNewswire
Published on: 2025-09-27 16:04:15 - newser.com
What the charts say about Instil Bio Inc. todayBull Run & Weekly High Potential Stock Alerts - newser.com
What analysts say about INmune Bio Inc stockTechnical Breakout Signals & Free Daily Stock Hotspot Analysis - Early Times
Can Climb Bio Inc. recover in the next quarter2025 Market Overview & AI Enhanced Execution Alerts - newser.com
Gossamer Bio Announces Presentations at the European Respiratory Society (ERS) Congress 2025 - Business Wire
Cabaletta Bio, Inc. $CABA Shares Purchased by Acadian Asset Management LLC - MarketBeat
INmune Bio, Inc. (NASDAQ:INMB) Short Interest Down 29.8% in August - MarketBeat
Co-Diagnostics, Inc. Announces Closing of $3.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - BioSpace
Is KALA BIO Inc. stock ready for a breakoutEarnings Recap Report & Long-Term Safe Investment Plans - newser.com
Kalexo enters dyslipidemia fray with preclinical siRNA candidate - BioWorld MedTech
bluebird bio Rebrands as Genetix Biotherapeutics, Returning to Its Foundational Roots - Business Wire
100% Clinical Response: Palisade Bio's Novel UC Drug Shows Promise in Phase 1b with Zero Serious Side Effects - Stock Titan
Can Palisade Bio Inc. recover in the next quarter2025 Momentum Check & Free Fast Entry Momentum Trade Alerts - newser.com
Passage Bio Inc. stock retracement – recovery analysisMarket Risk Report & Safe Entry Momentum Stock Tips - newser.com
Pattern recognition hints at Boundless Bio Inc. upsideJuly 2025 Momentum & Fast Gain Swing Alerts - newser.com
Nuvation Bio: A Rare Gem In The Risky Biotech Space (NYSE:NUVB) - Seeking Alpha
Does Climb Bio Inc. show high probability of reboundJuly 2025 Update & Verified Momentum Stock Watchlist - newser.com
Can GRI Bio Inc. recover in the next quarterGlobal Markets & High Accuracy Buy Signal Tips - newser.com
Will GRI Bio Inc. continue its uptrend2025 Year in Review & Stock Portfolio Risk Control - newser.com
Gossamer Bio, Inc. (NASDAQ:GOSS) Receives $8.50 Average Price Target from Brokerages - Defense World
First-Ever Phase 3 Trial for Stargardt Disease: Belite Bio's Tinlarebant Could Be Breakthrough Treatment - Stock Titan
GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”) - GlobeNewswire
Gossamer Bio stock upgraded at UBS (GOSS:NASDAQ) - Seeking Alpha
In 8 Bio Inc Azioni (INAB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.09%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):